|Articles|June 1, 2019
- Applied Clinical Trials-06-01-2019
- Volume 28
- Issue 6
Applied Clinical Trials, June 2019 Issue (PDF)
Click the title above to open the Applied Clinical Trials June 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 7 years ago
Master Protocol Guidance in Cancer R&D: Impact on Industryabout 7 years ago
The Benefits of RWD & RWE in Oncology Trialsabout 7 years ago
Glimpsing the Future of Clinical Trial Designabout 7 years ago
FDA Facilitates Expanded Access for Cancer Drugsabout 7 years ago
Real-World Evidence Gains Traction for Informing Clinical Researchabout 7 years ago
News Notesabout 7 years ago
Navigating Drug Development Through More Turbulent Watersabout 7 years ago
Building a Physician Referral Network: A Case Studyabout 7 years ago
Predicting the Probability of Success in Clinical Drug Developmentabout 7 years ago
Reveling in 2018's Revealing Drug and Biologic ApprovalsAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market
2
ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation
3
ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch
4
Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial
5